1 / 21

Defining immunodeficiency in heterotaxy syndrome

Defining immunodeficiency in heterotaxy syndrome. Terence Prendiville, MD Pediatric Cardiology fellow Boston Children’s Hospital Heterotaxy Hope Foundation, Minneapolis, MN 06/22/2013. Asplenia and polysplenia : functionally under active.

nellis
Download Presentation

Defining immunodeficiency in heterotaxy syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Defining immunodeficiency in heterotaxy syndrome Terence Prendiville, MD Pediatric Cardiology fellow Boston Children’s Hospital Heterotaxy Hope Foundation, Minneapolis, MN 06/22/2013

  2. Asplenia and polysplenia: functionally underactive • Normal role of spleen: ‘filter’ for the bloodstream. • - mops up defective or old red blood cells • - removes specific forms of ‘encapsulated’ bacteria that normally get coated in antibodies and labelled for destruction

  3. (radiological) Methods of evaluating the spleen:

  4. Historically, how do we ‘measure’ splenic function? • Howell Jolly bodies Pocked erythrocyte count

  5. The evidence for Infectious risks still present even under current best-practice guidelines:

  6. The evidence for Infectious risks still present even under current best-practice guidelines: • Out of 29 patients with heterotaxy syndrome (1999-2009): • 7 developed sepsis (24%) • 6/7 were on preventative (prophylactic) antibiotics (86%) • 5/7 polysplenia, 2/7 asplenia • Sepsis was associated with a 44% mortality

  7. What are the bugs evading the immune system in patients with heterotaxy? • (polysaccharide) encapsulated organisms: • Haemophilus influenza type B (meningitis) • Streptococcus pneumonia (sepsis, pneumonia) • Neisseria meningitides (meningitis) • Group B streptococcus (sepsis around birth) • Klebsiella pneumonia (sepsis) • Salmonella typhi (typhoid fever)

  8. Keegan’s spirit foundation-funded research project investigating the risk of infection in heterotaxy syndrome

  9. 2005-2010 CICU DATACardiovascular Program (CVP) Patients CLABSI= central line associated bloodstream infection VAP= ventilator associated pneumonia UTI= catheter associated urinary tract infection *based on midnight census on 8S*

  10. 155 days 84 days

  11. Novel ‘biomarkers’ of sepsis in heterotaxy • Howell Jolly Bodies in red cells: Quantitative analysis by red cell flow cytometry – Litron laboratories • IgM memory B cells: Memory B cells - immunological ‘memory’ after activation (30-60% of B cell pool) IgM memory B cells – normally mature in the spleen and are involved in the immune response to encapsulated organisms

  12. Analysis of IgM Memory B cells in the peripheral blood of a splenectomized patient, a hyposplenic Inflammatory Bowel Disease (IBD) patient, an eusplenic IBD patient, and a healthy control

  13. Goal to correlate the biomarkers in infancy with subsequent risk of (serious) infection • Tool to ‘predict’ or ‘forecast’ which children are at highest risk of infection • Ability to ‘flag’ them as ‘high risk’ of infection – in hospital and at home • Instigate early and aggressive therapy for evolving infections • Reinforce adherence to strict sterile protocol in care of patient (as per an immunocompromised patient)

  14. Initial recruitment • Pilot study targeting the patients thought to be at highest risk of infection first – collate the strongest evidence possible to provide the scientific rationale for a larger (broader) follow-up study

  15. Study timeline • 6 months (from July 2013) to recruit and complete enrollment of 10 heterotaxy syndrome patients and 10 controls • A further 3 months to finish study (12 weeks from last patient recruited) • 3-6 months to analyze the data, write the report and submit grant applications (AHA) for a larger, multi-site study (assuming pilot study found promising leads)

  16. General Recommendations – early warning • Recommend seeking medical attention with: • Fever >100.4F / 38C • Other signs of infection: irritability, lethargy (less alert), poor feeding / vomiting, breathlessness, cool peripheries, rash • Trust your instinct as their parent! The glass test: meningitis rash

  17. General recommendations: vaccination and antibiotic prophylaxis • Your doctor or immunologist may recommend vaccination with an two additional vaccines: • Pneumococcal polysaccharide (PPSV23) vaccine after 2 years of age. This vaccine covers a broader spectrum of bacteria that children with heterotaxy syndrome may be exposed to and is not part of the normal vaccination schedule. • Meningococcal vaccine (further details on exact dosing from the www.CDC.gov website).

  18. ? Pill-in-pocket approach to antibiotics with early signs of infection Ideally – blood culture and / or lumbar puncture would be done prior to starting broad-spectrum antibiotics Perhaps if travelling or no easy access to immediate medical care, a home supply of a broad spectrum antibiotic may be indicated to administer at the first sign of infection

  19. In summary • Susceptibility to infection (encapsulated organisms) is a risk in heterotaxy patients with both asplenia and polysplenia • The risk of infection is STILL relevant today • Promptly seek medical attention with signs of infection (even if many false alarms) • Be compliant with antibiotic therapy and consider broader vaccination coverage • Biomarkers identifying the highest risk heterotaxy syndrome patients are in development

More Related